"Etanercept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
| Descriptor ID |
D000068800
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232
|
| Concept/Terms |
TNFR-Fc Fusion Protein- TNFR-Fc Fusion Protein
- Fusion Protein, TNFR-Fc
- Protein, TNFR-Fc Fusion
- TNFR Fc Fusion Protein
- TNR-001
- TNR001
- TNR 001
- 001, TNR
- TNT Receptor Fusion Protein
- TNTR-Fc
|
Below are MeSH descriptors whose meaning is more general than "Etanercept".
Below are MeSH descriptors whose meaning is more specific than "Etanercept".
This graph shows the total number of publications written about "Etanercept" by people in this website by year, and whether "Etanercept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etanercept" by people in Profiles.
-
Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus. J Clin Rheumatol. 2017 Aug; 23(5):252-257.
-
Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis. BMC Musculoskelet Disord. 2017 05 30; 18(1):228.
-
Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
-
Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009 May; 36(5):914-7.
-
Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.
-
New therapeutic approaches for spondyloarthritis. Curr Opin Rheumatol. 2007 May; 19(3):259-64.
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
-
Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? J Drugs Dermatol. 2006 Oct; 5(9):903-4.
-
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8.
-
Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.